海正藥業(600267.SH)漲停 藥監局尚未正式受理法匹拉韋片藥品註冊申報資料
格隆匯2月3日丨海正藥業(600267.SH)公佈,公司A股股票於2020年1月23日、2月3日連續兩個交易日內收盤價格漲幅偏離值累計達到20%以上,根據《上海證券交易所交易規則》的有關規定,屬於股票交易異常波動。經公司自查,公司目前生產經營情況正常,不存在應披露而未披露的重大信息。
近日,公司從網絡上關注到有媒體報道中涉及到公司藥品法匹拉韋,現就相關情況做如下説明:
法匹拉韋片為廣譜抗病毒藥物,公司將按仿製藥申請生產,適應症為用於成人新型或復發流感的治療(僅限於其它抗流感病毒藥物治療無效或效果不佳時使用)。截至目前,國家藥品監督管理局尚未正式受理公司該產品的藥品註冊申報資料,公司也未收到相關特別審批的許可。請廣大投資者注意投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.